Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
1.
ACS Infect Dis ; 9(10): 1981-1992, 2023 10 13.
Artigo em Inglês | MEDLINE | ID: mdl-37708378

RESUMO

New drugs to treat tuberculosis which target intractable bacterial populations are required to develop shorter and more effective treatment regimens. The benzene amide ether scaffold has activity against intracellular Mycobacterium tuberculosis, but low activity against extracellular, actively replicating M. tuberculosis. We determined that these molecules have bactericidal activity against non-replicating M. tuberculosis but not actively replicating bacteria. Exposure to compounds depleted ATP levels in non-replicating bacteria and increased the oxygen consumption rate; a subset of molecules led to the accumulation of intrabacterial reactive oxygen species. A comprehensive screen of M. tuberculosis strains identified a number of under-expressing strains as more sensitive to compounds under replicating conditions including QcrA and QcrB hypomorphs. We determined the global gene expression profile after compound treatment for both replicating and nutrient-starved M. tuberculosis. We saw compound-dependent changes in the expression of genes involved in energy metabolism under both conditions. Taken together, our data suggest that the scaffold targets respiration in M. tuberculosis.


Assuntos
Mycobacterium tuberculosis , Tuberculose , Humanos , Antituberculosos/metabolismo , Benzeno/farmacologia , Éter/metabolismo , Éter/farmacologia , Éter/uso terapêutico , Amidas/farmacologia , Testes de Sensibilidade Microbiana , Tuberculose/tratamento farmacológico , Tuberculose/microbiologia , Etil-Éteres/metabolismo , Etil-Éteres/farmacologia , Etil-Éteres/uso terapêutico , Éteres/metabolismo , Éteres/farmacologia , Éteres/uso terapêutico
2.
J Evid Based Integr Med ; 28: 2515690X231152928, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36740925

RESUMO

Safe depigmenting agents are currently increasing in the cosmetic or pharmaceutical industry because various compounds have been found to have undesirable side effects. Therefore, the present study aimed to investigate the melanogenesis inhibitory effects of Prunus cerasoides Buch. -Ham. D. Don. flower extracts and their molecular mechanism in B16F10 mouse melanoma cells. Moreover, we also examined phenolic and flavonoid contents, antioxidant activity, chemical constituents of potential extracts, and molecular docking. The highest phenolic and flavonoid contents with the greatest scavenging activity were found in the butanol extract of the P. cerasoides flower compared to other extracts. From all extracts, only crude, diethyl ether, and butanol extracts showed an inhibition of mushroom tyrosinase activity, cellular tyrosinase activity, and melanin content as well as the downregulation of the gene expression of the microphthalmia-associated transcription factor (MITF), tyrosinase, tyrosinase-related protein-1 (TRP-1), and tyrosinase-related protein-2 (TRP-2) in α-MSH-stimulated B16F10 cells. Based on the molecular docking study, n-hexadecanoic acid, heptadecanoic acid, octadecanoic acid, 9,12-octadecadienoic acid, 9,12,15-octadecanoic acid, and eicosanoic acid might show an inhibitory effect against tyrosinase and MITF. In conclusion, this finding demonstrates that both the diethyl ether and butanol extracts of the P. cerasoides flower can effectively reduce tyrosinase activity and melanin synthesis through the downregulation of the melanogenic gene expression in B16F10 cells and through the molecular docking study. Taken together, the diethyl ether and butanol extracts of the P. cerasoides flower could be an anti-melanogenic ingredient for hyperpigmentary or melasma treatment.


Assuntos
Melanoma Experimental , Monofenol Mono-Oxigenase , Animais , Camundongos , Butanóis/uso terapêutico , Éter/uso terapêutico , Flavonoides , Melaninas/uso terapêutico , Melanoma Experimental/tratamento farmacológico , Melanoma Experimental/metabolismo , Simulação de Acoplamento Molecular , Monofenol Mono-Oxigenase/genética , Monofenol Mono-Oxigenase/metabolismo
3.
Drug Dev Res ; 84(1): 121-140, 2023 02.
Artigo em Inglês | MEDLINE | ID: mdl-36461610

RESUMO

Berberrubine is a naturally occurring isoquinoline alkaloid and a bioactive metabolite of berberine. Berberine exhibits a wide range of pharmacological activities, including cholinesterase inhibition. The cholinesterase inhibitors provide symptomatic treatment for Alzheimer's disease; however, multitarget-directed ligands have the potential as disease-modifying therapeutics. Herein, we prepared a series of C9-substituted berberrubine derivatives intending to discover dual cholinesterase and beta-site amyloid-precursor protein cleaving enzyme 1 (BACE-1) inhibitors. Most synthesized derivatives possessed balanced dual inhibition (AChE and BChE) activity in the submicromolar range and a moderate inhibition against BACE-1. Two most active ester derivatives, 12a and 11d, display inhibition of AChE, BChE, and BACE-1. The 3-methoxybenzoyl ester derivative, 12a, inhibits electric eel acetylcholinesterase (EeAChE), equine serum butyrylcholinesterase (eqBChE), and human hBACE-1 with IC50 values of 0.5, 4.3, and 11.9 µM, respectively and excellent BBB permeability (Pe = 8 × 10-6 cm/s). The ester derivative 12a is metabolically unstable; however, its ether analog 13 is stable in HLM and exhibits inhibition of AChE, BChE, and BACE-1 with IC50 values of 0.44, 3.8, and 17.9 µM, respectively. The ether analog also inhibits self-aggregation of Aß and crosses BBB (Pe = 7.3 × 10-6 cm/s). Administration of 13 at 5 mg/kg (iv) in Wistar rats showed excellent plasma exposure with AUC0-∞ of 28,834 ng min/ml. In conclusion, the multitargeted berberrubine ether derivative 13 is CNS permeable and has good ADME properties.


Assuntos
Doença de Alzheimer , Berberina , Ratos , Animais , Cavalos , Humanos , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/metabolismo , Butirilcolinesterase/metabolismo , Acetilcolinesterase/metabolismo , Berberina/farmacologia , Relação Estrutura-Atividade , Éter/uso terapêutico , Simulação de Acoplamento Molecular , Ratos Wistar , Inibidores da Colinesterase , Etil-Éteres/uso terapêutico , Éteres/uso terapêutico , Estrutura Molecular
4.
J Spec Oper Med ; 18(2): 142-146, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29889973

RESUMO

Medical services in the austere and limited environment often require therapeutics and practices uncommon in modern times due to a lack of availability, affordability, or expertise in remote areas. In this setting, diethyl ether, or simply ether anesthesia, still serves a role today as an effective inhalation agent. An understanding of ether as an anesthetic not only illustrates the evolution in surgical anesthesia but also demonstrates ether's surviving function and durable use as a practical agent in developing nations. Although uncommon, it is not unseen, so a working knowledge should be understood if observation and advocacy for patients receiving this method of anesthesia are experienced.


Assuntos
Anestesia/métodos , Anestesiologia/instrumentação , Éter , Medicina Militar , Administração por Inalação , Desenho de Equipamento , Éter/administração & dosagem , Éter/uso terapêutico , Humanos , Medicina Militar/educação , Medicina Militar/métodos , Militares , Guerra
5.
J Anesth Hist ; 4(1): 9-10, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-29559092

RESUMO

In 1847, British anesthesia pioneer John Snow (1813-1858) observed that patients did not manifest cyanosis during induction with hypoxic mixtures of ether vapor in air. He hypothesized a molecular mechanism that would be understood over a century later as the second gas effect.


Assuntos
Anestesia/história , Anestesiologia/história , Anestesia/métodos , Anestesiologia/métodos , Éter/história , Éter/uso terapêutico , História do Século XIX , Humanos , Óxido Nitroso/história , Óxido Nitroso/uso terapêutico , Reino Unido
6.
Colorectal Dis ; 18(3): 247-54, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26299511

RESUMO

AIM: The correct analysis of lymph node status is one of the most important parameters for the accurate pathological diagnosis of colorectal cancer. Our aim was to evaluate the number of lymph nodes among the specimens obtained from colorectal resections due to colorectal cancer, before and after the routine use of a lymph node revealing solution (LNRS). METHOD: Data from 780 surgical specimens from patients of both genders with colorectal cancer were studied. The cases were divided chronologically into two groups: the conventional group included 497 specimens treated with conventional methods, i.e. without the use of the LNRS (January 2000 to July 2007), and the LNRS group included 283 specimens examined through the routine use of this solution (August 2007 to July 2012). RESULTS: Most patients were female (57.4%) with a median age of 62 years. The median lymph node number was 18, and 75.9% of the cases (592) had 12 or more nodes dissected. Lymph node metastases were noted in 334 cases (42.8%). A median of 24 lymph nodes was dissected in the LNRS group compared to 15 in the conventional group (P < 0.001). The LNRS group had 9.2% of cases with fewer than 12 lymph nodes dissected compared with 32.6% in the conventional group (P < 0.001). CONCLUSIONS: The use of the LNRS increases the number of lymph nodes obtained from colorectal cancer surgical specimens and can help to reduce the number of cases with < 12 lymph nodes.


Assuntos
Ácido Acético/uso terapêutico , Neoplasias Colorretais/patologia , Etanol/uso terapêutico , Éter/uso terapêutico , Formaldeído/uso terapêutico , Indicadores e Reagentes , Linfonodos/patologia , Biópsia de Linfonodo Sentinela/métodos , Coloração e Rotulagem/métodos , Adenocarcinoma/patologia , Adenocarcinoma/cirurgia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Colectomia/métodos , Neoplasias Colorretais/cirurgia , Feminino , Humanos , Indicadores e Reagentes/química , Linfonodos/cirurgia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Estudos Retrospectivos , Adulto Jovem
8.
Chemotherapy ; 60(5-6): 302-9, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-26088465

RESUMO

Daucus carota (DC) is a herb used in folklore medicine in Lebanon to treat numerous diseases including cancer. Recent studies in our laboratory on DC oil and its fractions revealed potent anticancer activities in vitro and in vivo. The present study aims to investigate the effect of the most potent DC fraction, pentane/diethyl ether (50:50), on lung, skin, breast and glioblastoma cancer cell motility and invasion. Upon treatment, a pronounced decrease in cancer cell motility was observed in the 4 cell lines. The treatment also led to a decrease in cancer cell invasion and an increased cell adhesion. Additionally, the DC fraction caused a decrease in the activation of the ρ-GTPases Rac and CDC42, a finding that may partially explain the treatment-induced decrease in cell motility. The current study demonstrates a crucial effect of the DC pentane/diethyl ether fraction on cancer cell motility and metastasis, making it a potential candidate for cancer therapy specifically targeting cancer motility and metastasis.


Assuntos
Movimento Celular/efeitos dos fármacos , Daucus carota , Éter/uso terapêutico , Invasividade Neoplásica/prevenção & controle , Pentanos/uso terapêutico , Extratos Vegetais/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Éter/isolamento & purificação , Éter/farmacologia , Feminino , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/patologia , Melanoma Experimental , Invasividade Neoplásica/patologia , Pentanos/isolamento & purificação , Pentanos/farmacologia , Extratos Vegetais/isolamento & purificação , Folhas de Planta , Óleos de Plantas/isolamento & purificação , Óleos de Plantas/uso terapêutico , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/patologia
9.
Cell Oncol (Dordr) ; 36(3): 247-57, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23619943

RESUMO

BACKGROUND: The heterogeneity of liver cancer, in particular hepatocellular carcinoma (HCC), portrays the requirement of multiple targets for both its treatment and prevention. Multifaceted agents, minimally or non-toxic for normal hepatocytes, are required to address the molecular diversity of HCC, including the resistance of putative liver cancer stem cells to chemotherapy. METHODS: We designed and synthesized two fatty acid ethers of isopropylamino propanol, C16:0-AIP-1 and C18:1-AIP-2 (jointly named AIPs), and evaluated their anti-proliferative effects on the human HCC cell line Huh7 and the murine hepatoma cell line BNL 1MEA.7R.1, both in vitro and in an in vivo allograft mouse model. RESULTS: We found that AIP-1 and AIP-2 inhibited proliferation and caused cell death in both Huh7 and BNL 1MEA.7R.1 cells. Importantly, AIP-1 and AIP-2 were found to block the activation of putative liver cancer stem cells as manifested by suppression of clonal 'carcinosphere' development in growth factor-free and anchorage-free medium. The AIPs exhibited a relatively low toxicity against normal human or rat hepatocytes in primary cultures. In addition, we found that the AIPs utilized multifaceted pathways that mediate both autophagy and apoptosis in HCC, including the inhibition of AKTs and CAMK-1. In immune-competent mice, the AIPs significantly reduced BNL 1MEA.7R.1 cell-driven tumor allograft development, with a higher efficiency than sorafenib. A combination of AIP-1 + AIP-2 was most effective in reducing the tumor allograft incidence. CONCLUSIONS: AIPs represent a novel class of simple fatty acid derivatives that are effective against liver tumors via diverse pathways. They show a low toxicity towards normal hepatocytes. The addition of AIPs may represent a new avenue towards the management of chronic liver injury and, ultimately, the prevention and treatment of HCC.


Assuntos
Amidas/farmacologia , Éter/farmacologia , Ácidos Graxos/farmacologia , Neoplasias Hepáticas/patologia , Transplante de Neoplasias , Amidas/síntese química , Amidas/química , Amidas/uso terapêutico , Animais , Apoptose/efeitos dos fármacos , Autofagia/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Sistema Livre de Células , Modelos Animais de Doenças , Regulação para Baixo/efeitos dos fármacos , Éter/síntese química , Éter/química , Éter/uso terapêutico , Ácidos Graxos/uso terapêutico , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Hepatócitos/patologia , Humanos , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/metabolismo , Camundongos , Inibidores de Proteínas Quinases/farmacologia , Proteólise/efeitos dos fármacos , Espectrina/metabolismo , Esferoides Celulares/efeitos dos fármacos , Esferoides Celulares/metabolismo , Esferoides Celulares/patologia
10.
Theranostics ; 2(12): 1160-73, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23382773

RESUMO

A focused library of twenty-one cationic poly(amino ethers) was synthesized following ring-opening polymerization of two diglycidyl ethers by different oligoamines. The polymers were screened in parallel for plasmid DNA (pDNA) delivery, and transgene expression efficacies of individual polymers were compared to those of 25 kDa polyethylenimine (PEI), a current standard for polymer-mediated transgene delivery. Seven lead polymers that demonstrated higher transgene expression than PEI in pancreatic and prostate cancer cells lines were identified from the screen. All seven lead polymers showed highest transgene expression at a polymer:pDNA weight ratio of 5:1 in the MIA PaCa-2 pancreatic cancer cell line. Among the conditions studied, transgene expression efficacy correlated with minimal polymer cytotoxicity but not polyplex sizes. In addition, this study indicated that methylene spacing between amine centers in the monomers, amine content, and molecular weight of the polymers are all significant factors and should be considered when designing polymers for transgene delivery. A lead effective polymer was employed for coating gold nanorods, leading to theranostic nanoassemblies that possess combined transgene delivery and optical imaging capabilities, leading to potential theranostic systems.


Assuntos
Éter/uso terapêutico , Técnicas de Transferência de Genes , Ouro/química , Nanotubos/química , Poliaminas/uso terapêutico , Transgenes/genética , Aminas/química , Morte Celular , Linhagem Celular Tumoral , Diagnóstico por Imagem , Éter/síntese química , Éter/química , Expressão Gênica , Humanos , Hidrodinâmica , Luciferases/metabolismo , Peso Molecular , Tamanho da Partícula , Poliaminas/síntese química , Poliaminas/química , Espectrofotometria Ultravioleta , Eletricidade Estática
15.
Rev Neurol ; 28 Suppl 1: S59-64, 1999 Jan.
Artigo em Espanhol | MEDLINE | ID: mdl-10778491

RESUMO

INTRODUCTION: We found that patients with the Zellweger syndrome and other generalized peroxisomal disorders have a dramatic decrease of docosahexaenoic acid (DHA, 22:6n-3) in the blood, brain, retina and other tissues. DHA is believed to play an important role in the brain and retina. DEVELOPMENT: Patients with the Zellweger syndrome and its variants have severe cerebral and retinal defects that could be related to their DHA deficiency. With this rationale, we have been treating peroxisomal-disorder patients with a DHA derivative of a high degree of purity (DHA ethyl ester, > 90% pure) since 1991. So far, we have treated 13 DHA-deficient peroxisomal patients, one with the classic Zellweger syndrome and 12 with milder variants of the disease. This paper presents the follow-up of these DHA-treated patients. In summary, we have found important improvements in liver function, in the plasmalogen levels and in the two ratios 26:0/22:0 y 26:1/22:0, diagnostic of the disease. We have also found clear clinical improvements in most cases. Most significantly, magnetic resonance imaging has shown advances in brain myelination, so far in 6 of the treated patients. CONCLUSION: We strongly recommend treatment with DHA ethyl ester in all DHA-deficient patients with generalized peroxisomal disorders. Logically, treatment should be started as soon as possible, in the hope of preventing cerebral and visual damage.


Assuntos
Ácidos Docosa-Hexaenoicos/uso terapêutico , Transtornos Peroxissômicos/tratamento farmacológico , Encéfalo/patologia , Criança , Pré-Escolar , Doenças Desmielinizantes/patologia , Ácidos Docosa-Hexaenoicos/sangue , Éter/uso terapêutico , Humanos , Lactente , Imageamento por Ressonância Magnética , Transtornos Peroxissômicos/patologia , Resultado do Tratamento
16.
Eur J Clin Pharmacol ; 54(3): 231-5, 1998 May.
Artigo em Inglês | MEDLINE | ID: mdl-9681665

RESUMO

OBJECTIVE: The aim of this investigation was to elucidate whether the analgesic effect was due to the local aspirin or to the systemic drug. This was done by comparing skin and plasma levels of acetylsalicylic acid (ASA) and salicylic acid (SA) after topically administered ASA/diethyl ether (ADE) mixture in acute herpetic neuralgia (AHN) and postherpetic neuralgia (PHN). The analgesia and the plasma and skin levels of ASA were also determined after oral administration of aspirin. METHODS: Nineteen patients, 11 (57.9%) with AHN and 8 (42.1 %) with PHN were given, on different days, a single 500-mg oral dose of ASA or a topical dose (750 mg) of (ADE) daubed onto the painful skin. The analgesic effect was assessed by means of a visual analogue scale (VAS). Overall pain relief was graded as: excellent, good, fair, or poor. AHN as well as PHN patients had severe pain at baseline (6.83 and 5.93). Levels of ASA and SA in plasma and in the stratum corneum after adhesive tape stripping of the treated area were determined by HPLC. RESULTS: After ADE application, the analgesic effect was very rapid and VAS scores were lower than at baseline. Pain significantly decreased by 82.6% after topical and 15.4% after oral ASA. After ADE, 95% of the patients had excellent or good pain relief, but after oral administration 79% of the patients had a poor response. Pain relief was similar in the two subgroups after ADE. Skin concentrations of ASA, but not of SA, after ADE were about 80- to 100-fold those after oral administration. Levels of ASA and SA in plasma after oral administration were similar to those previously found, but after ADE were undetectable or very low. Patients with excellent pain relief showed a trend towards higher ASA skin concentrations. CONCLUSIONS: The analgesic effect can be obtained only after topical administration, because by this route the skin levels of ASA are much higher than after oral administration. The mechanism is exclusively local; there are no active drugs in plasma after topical administration.


Assuntos
Anti-Inflamatórios não Esteroides/sangue , Aspirina/sangue , Pele/química , Doença Aguda , Administração Oral , Administração Tópica , Idoso , Analgésicos/uso terapêutico , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/sangue , Anti-Inflamatórios/uso terapêutico , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/uso terapêutico , Aspirina/administração & dosagem , Aspirina/uso terapêutico , Estudos Cross-Over , Método Duplo-Cego , Éter/administração & dosagem , Éter/uso terapêutico , Feminino , Herpes Zoster/complicações , Herpes Zoster/tratamento farmacológico , Infecções por Herpesviridae/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Neuralgia/tratamento farmacológico , Neuralgia/virologia , Dor/tratamento farmacológico , Medição da Dor/efeitos dos fármacos , Salicilatos , Ácido Salicílico , Solventes/administração & dosagem , Solventes/uso terapêutico , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA